Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
bisphosphonate |
| gptkbp:approvedBy |
1995
|
| gptkbp:ATCCode |
M05BA04
|
| gptkbp:bioavailability |
0.6%
|
| gptkbp:brand |
gptkb:Fosamax
|
| gptkbp:CASNumber |
121268-17-5
|
| gptkbp:chemicalFormula |
C4H13NO7P2
|
| gptkbp:contraindication |
hypocalcemia
esophageal abnormalities |
| gptkbp:discoveredBy |
gptkb:Merck_&_Co.
|
| gptkbp:eliminationHalfLife |
over 10 years (in bone)
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
alendronic acid
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits osteoclast-mediated bone resorption
|
| gptkbp:metabolism |
not metabolized
|
| gptkbp:molecularWeight |
249.1 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gastrointestinal upset
musculoskeletal pain esophageal irritation |
| gptkbp:synonym |
gptkb:alendronate
4-amino-1-hydroxybutylidene bisphosphonate |
| gptkbp:usedFor |
gptkb:bone
gptkb:Paget's_disease_of_bone |
| gptkbp:bfsParent |
gptkb:M01AH01
|
| gptkbp:bfsLayer |
7
|